SMMT Stock — Summit Therapeutics Inc.: Cash, EV, Pipeline

Share price

$17.85

Market cap

$14,239.8M

Cash

$690.7M

Enterprise value

$13,549.1M

Balance sheet

Cash	$690.7M
Debt	$0.0M
Net cash	$690.7M
Enterprise value	$13,549.1M
Basic shares	793.1M shares
Fully diluted shares	929.9M shares
Fully diluted market cap	$16,599.2M
Cash per share	$0.87

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SMMT daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Sep 14 - Oct 26	Ivonescimab	Phase 2	Biliary Tract Cancer	—
Oct 13 - Nov 24	Ivonescimab	Phase 2	Metastatic Esophageal Adenocarcinoma; Advanced Esophageal Adenocarcinoma; Metastatic Gastric Adenocarcinoma	—
May 13 - Jun 24	Ivonescimab Injection	Phase 3	Non-Small Cell Lung Cancer	—
Jul 12 - Aug 23	Ivonescimab Injection	Phase 3	Metastatic Colorectal Cancer (CRC)	—
Feb 11 - Mar 25	Ivonescimab Injection	Phase 3	Non-Small Cell Lung Cancer	—
Jun 12 - Jul 24	Daraxonrasib	Phase 2	Advanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC)	—
Sep 12 - Oct 24	Ivonescimab	Phase 2	Metastatic Colorectal Cancer	—
Dec 12, 2030 - Jan 23, 2031	Ivonescimab Dose 1	Phase 3	Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma (UC)	—
Feb 12 - Mar 25	Ivonescimab	Phase 2	Non Small Cell Lung Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Ivonescimab

Stage not disclosed · Active Modality: bispecific antibody

Aliases AK112, SMT112

Target PD-1 / VEGF

Partnerships Akeso: in-license (Dec 2022, closed Jan 2023; expanded Jun 2024) covering US, Canada, Europe, Japan, Latin America, Middle East, Africa. Summit controls clinical development, regulatory filings, and commercial strategy in the Licensed Territory.

Indications

Oncology (Stage not disclosed)

Status note Novel potential first-in-class bispecific antibody combining PD-1 blockade with anti-VEGF in a single molecule; in clinical development in the Licensed Territory. Filing excerpts do not state specific trials, phases, or indications. Ridinilazole was divested via asset purchase agreement (Jun 2026) and is no longer a Summit asset.

Per-asset detail extracted from the 10-Q filed 2026-07-23. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Ivonescimab Injection
Lead indication	Non-Small Cell Lung Cancer
Lead phase	Phase 3
Active trials	5
Collaborator trials	26

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06767514	Phase 3	Recruiting	Sponsor	SMMT	—	Non-Small Cell Lung Cancer	—
NCT07228832	Phase 3	Recruiting	Sponsor	SMMT	—	Metastatic Colorectal Cancer (CRC)	—
NCT05899608	Phase 3	Recruiting	Sponsor	SMMT	—	Non-Small Cell Lung Cancer	—
NCT07815665	Phase 3	Recruiting	Sponsor	SMMT	—	Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma (UC)	—
NCT06396065	Phase 3	Active, not recruiting	Sponsor	SMMT	—	Non-Squamous Non-small Cell Lung Cancer	—
NCT07264075	Phase 3	Recruiting	Collaborator	Groupe Oncologie Radiotherapie Tete et Cou	—	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)	—
NCT06840834	Phase 2	Recruiting	Collaborator	Intergroupe Francophone de Cancerologie Thoracique	—	Pleural Mesotheliomas	—
NCT07070466	Phase 2	Recruiting	Collaborator	Massachusetts General Hospital	—	Stomach Cancer Stage IV; Esophagus Cancer; Stomach Cancer	—
NCT06925724	Phase 2	Recruiting	Collaborator	Memorial Sloan Kettering Cancer Center	—	Endometrial Cancer; Cervical Cancer	—
NCT06980077	Phase 2	Recruiting	Collaborator	Jonsson Comprehensive Cancer Center	—	Thymus Carcinoma	—
NCT07094685	Phase 2	Recruiting	Collaborator	University of Michigan Rogel Cancer Center	—	Advanced Head and Neck Squamous Cell Carcinoma; Resectable Head and Neck Squamous Cell Carcinoma; Stage II Head and Neck Cutaneous Squamous Cell Carcinoma	—
NCT06529718	Phase 2	Recruiting	Collaborator	UNICANCER	—	Biliary Tract Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (5 as sponsor, 26 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 31 active trials for Summit Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	32,786,348	-3,604,715	2.39%	2026-08-14
Logos Global Management	1,350,000	+1,350,000	0.85%	2026-08-14
ADAR1 Capital Management	191,869	+100,000	0.13%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

SMMT — Summit Therapeutics Inc.